The Transcription Factor Nuclear Factor-kappa B and Cancer

Clinical Oncology

Volumn 19, Issue 2, 2007, Pages 154-161

  Escarcega R O ^a   Fuentes Alexandro, S ^b   Garcia Carrasco M ^b   Gatica, A ^a   Zamora, A ^c  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

^c HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

Author keywords

Cancer; NF B; oncogenesis

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; AS 602868; BORTEZOMIB; CORTICOSTEROID; CYCLIN D1; CYTARABINE; DOXORUBICIN; ESTROGEN DERIVATIVE; ETOPOSIDE; FLICE INHIBITORY PROTEIN; I KAPPA B; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESALAZINE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN DERIVATIVE; PROTEASOME INHIBITOR; PROTEIN BCL XL; PROTEIN P52; RESVERATROL; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; SULINDAC SULFIDE; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VON HIPPEL LINDAU PROTEIN; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; CYTOPLASM; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; ESOPHAGEAL ADENOCARCINOMA; GENE ACTIVATION; HUMAN; INFLAMMATION; LIVER CELL CARCINOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER;

APOPTOSIS; CELL NUCLEUS; HUMANS; NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 33846570444     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2006.11.013     Document Type: Article

References (91)

1. Sen R., and Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein NF-κB by a posttranslational mechanism. Cell 47 (1986) 921-928
2. Ghosh S., and Karin M. Missing pieces in the NF-kappaB puzzle. Cell 109 Suppl (2002) S81-S96
3. Karin M., and Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 3 (2002) 221-227
4. Karin M., and Delhase M. The I kappaB kinase (IKK) and NF-kappaB: key elements of proinflammatory signalling. Semin Immunol 12 (2000) 85-98
5. Ghosh S., May M., and Kopp E. NF-κB and Rel proteins: evolutionarily conserved mediators of the immune response. Annu Rev Immunol 16 (1998) 225-260
6. Beg A., Sha W., Bronson R., Ghosh S., and Baltimore D. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-κB. Nature 376 (1995) 167-170
7. Lallemand-Breitenbach V., and de The H. CK2 and PML: regulating the regulator. Cell 126 (2006) 244-245
8. Li Z.W., Chu W., Hu Y., et al. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. J Exp Med 189 (1999) 1839-1845
9. Senftleben U., Cao Y., Xiao G., et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 293 (2001) 1495-1499
10. Vincenti M.P., Coon C.I., and Brinckerhoff C.E. Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts. Arthritis Rheum 41 (1998) 1987-1994
11. Miyazawa K., Mori A., Yamamoto K., and Okudaira H. Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: spontaneous activation of NF-kappa B and CBF-1. Am J Pathol 152 (1998) 793-803
12. Rahman A., Anwar K.N., True A.L., and Malik A.B. Thrombin-induced p65 homodimer binding to downstream NF-kappa B site of the promoter mediates endothelial ICAM-1 expression and neutrophil adhesion. J Immunol 162 (1999) 5466-5476
13. Tak P.P., and Firestein G.S. NF-κB: a key role in inflammatory diseases. J Clin Invest 107 (2001) 7-11
14. Han Z.N., Boyle D.L., Manning A.M., and Firestein G.S. AP-1 and NF-kappa B regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28 (1998) 197-208
15. Hart L.A., Krishnan V.L., Adcock I.M., Barnes P.J., and Chung K.F. Activation and localization of transcription factor, nuclear factor-kappaB in asthma. Am J Respir Crit Care Med 158 (1998) 1585-1592
16. Van Den Brink G.R., Ten Kate F.J., Ponsioen C.Y., et al. Expression and activation of NF-kappa B in the antrum of the human stomach. J Immunol 164 (2000) 3353-3359
17. Zhang G., and Ghosh S. Toll-like receptor-mediated NF-κB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest 107 (2001) 13-19
18. Anderson K.V. Toll signaling pathways in the innate immune response. Curr Opin Immunol 12 (2000) 13-19
19. Muzio M., Polentarutti N., Bosisio D., Prahladan M.K., and Mantovani A. Toll-like receptors: a growing family of immune receptors that are differentially expressed and regulated by different leukocytes. J Leukoc Biol 67 (2000) 450-456
20. Mattson M.P., and Camandola S. NF-κB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 107 (2001) 247-254
21. Kerr J.F., Wyllie A.H., and Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26 (1972) 239-257
22. Wyllie A.H., Kerr J.F., and Currie A.R. Cell death: the significance of apoptosis. Int Rev Cytol 68 (1980) 251-306
23. Danial N.N., and Korsmeyer S.J. Cell death: critical control points. Cell 116 (2004) 205-219
24. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
25. Luo J.-L., Kamata H., and Karin M. IKK/NF-κB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 115 (2005) 2625-2632
26. Kucharczak J., Simmons M.J., Fan Y., and Gelinas C. To be or not to be: NF-kappa B is the answer. Role of Rel/NF-kappa B in the regulation of apoptosis. Oncogene 22 (2003) 8961-8982
27. Maeda S., Chang L., Li Z.W., Luo J.L., Leffert H., and Karin M. IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity 19 (2003) 725-737
28. Papa S., Zazzeroni F., Pham C.G., Bubici C., and Franzoso G. Linking JNK signaling to NF-kappaB: a key to survival. J Cell Sci 117 (2004) 5197-5208
29. Sakon S., Xue X., Takekawa M., et al. NF-kappaB inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK activation and necrotic cell death. EMBO J 22 (2003) 3898-3909
30. Fiers W., Beyaert R., Declercq W., and Vandenabeele P. More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene 18 (1999) 7719-7730
31. Sasazuki T., Okazaki T., Tada K., et al. Genome wide analysis of TNF-inducible genes reveals that antioxidant enzymes are induced by TNF and responsible for elimination of ROS. Mol Immunol 41 (2004) 547-551
32. Ventura J.J., Cogswell P., Flavell R.A., Baldwin Jr. A.S., and Davis R.J. JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species. Genes Dev 18 (2004) 2905-2915
33. Guttridge D.C., Albanese C., Reuther J.Y., Pestell R.G., and Baldwin Jr. A.S. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19 (1999) 5785-5799
34. Yamamoto Y., and Gaynor R.B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 107 (2001) 135-142
35. Wang C.Y., Guttridge D.C., Mayo M.W., and Baldwin Jr. A.S. NF-κB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 19 (1999) 5923-5929
36. Bian X., McAllister-Lucas L.M., Shao F., et al. NF-kappa B activation mediates doxorubicin-induced cell death in N-type neuroblastoma cells. J Biol Chem 276 (2001) 48921-48929
37. Dajee M., Lazarov M., Zhang J.Y., et al. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421 (2003) 639-643
38. Webster G.A., and Perkins N.D. Transcriptional cross talk between NF-kappa B and p53. Mol Cell Biol 19 (1999) 3485-3495
39. Ryan K.M., Enrst M.K., Rice N.R., and Vousden K.H. Role of NF-kappaB in p53-mediated programmed cell death. Nature 404 (2000) 892-897
40. Hiscott J., Kwon H., and Génin P. Hostile takeovers: viral appropriation of the NF-κB pathway. J Clin Invest 107 (2001) 143-151
41. Chu Z., DiDonato J., Hawiger J., and Ballard D. The Tax oncoprotein of HTLV-I associates with and persistently activates IκB kinases containing IKKα and IKKβ. J Biol Chem 273 (1998) 15891-15894
42. Baldwin A.S. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 107 (2001) 241-246
43. Finco T.S., Westwick J.K., Norris J.L., Beg A.A., Der C.J., and Baldwin Jr. A.S. Oncogenic Ha-Ras-induced signaling activates NF-κB transcriptional activity which is required for cellular transformation. J Biol Chem 272 (1997) 24113-24116
44. Reuther J., Reuther G., Cortez D., Pendergast A.M., and Baldwin A. A requirement for NF-κB activation in Bcr-Abl-mediated transformation. Genes Dev 12 (1998) 968-981
45. Pikarsky E., Porat R.M., Stein I., et al. NF-κB functions as a tumor promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
46. Tai D.I., Tsai S.L., Chang Y.H., et al. Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer 89 (2000) 2274-2281
47. Van Hogerlinden M., Rozell B.L., Ährlund-Richter L., and Toftgard R. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-κB signaling. Cancer Res 59 (1999) 3299-3303
48. Greten F.R., Eckmann L., Greten T.F., et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated colon cancer. Cell 118 (2004) 285-296
49. Maeda S., Kamata H., Luo J.-L., Leffert H., and Karin M. IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121 (2005) 977-990
50. Arsura M., and Cavin L.G. Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 229 (2005) 157-169
51. Brandt S., Kwok T., Hartig R., König W., and Backert S. NF-κB activation and potentiation of proinflammatory responses by the Helicobacter pylori CagA protein. Proc Natl Acad Sci USA 102 (2005) 9300-9305
52. Abdel-Latif M.M.M., O'Riordan J., Windle H.J., et al. NF-κB activation in esophageal adenocarcinoma. Relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 239 (2004) 491-500
53. Zhou Y., Eppenberger-Castori S., Eppenberger U., and Benz C.C. The NF-κB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 12 (2005) S37-S46
54. Huang S., Robinson J.B., DeGuzman A., Bucana C.D., and Filder I.J. Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60 (2000) 5334-5339
55. Ghim S.J., Basu P.S., and Jenson A. Cervical cancer: etiology, pathogenesis, treatment and future vaccines. Asian Pac J Cancer Prev 3 (2002) 207-214
56. Furomoto H.I.M., and Irahara. Human papilloma virus (HPV) and cervical cancer. J Med Invest 49 (2002) 124-133
57. Shehata M., Shehata M., Shehata F., and Pater A. Dual apoptotic effect of Xrel c-Rel/NF-kappaB homolog in human cervical cancer cells. Cell Biol Int 28 (2004) 895-904
58. Shehata M.F. Rel/nuclear factor-kappa B apoptosis pathways in human cervical cancer cells. Cancer Cell Int 5 (2005) 10
59. Yang X., Hao Y., Ferenczy A., Tang S.C., and Pater A. Overexpression of anti-apoptotic gene BAG-I in human cervical cancer. Exp Cell Res 247 (1999) 200-207
60. Shinohara T., Miki T., Nishimura N., et al. Nuclear factor-κB-dependent expression of metastases suppressor KA11/CD82 gene in lung cancer cell lines expressing mutant p53. Cancer Res 61 (2001) 673-678
61. Dong J.-T., Suzuki H., Pin S.S., et al. Down regulation of KA11 metastases suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res 56 (1996) 4387-4390
62. Guo X., Friess H., Graber H.U., et al. KA11 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res 56 (1996) 4876-4880
63. Adachi M., Taki T., Ikei Y., Huang C.-L., Higashiyama M., and Miyake M. Correlation of KA11/CD82 gene expression with good prognosis in patients with non-small cell lung cancer. Cancer Res 56 (1996) 1751-1755
64. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma classification project. Blood 89 (1997) 3909-3918
65. Jemal A., Tiwari R.C., Murray T., et al. Cancer statistics. CA Cancer J Clin 54 (2004) 8-29
66. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol 13 (2001) 325-334
67. Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B cell lymphoma. N Engl J Med 346 (2002) 1937-1947
68. Shipp M.A., Ross K.N., Tamayo P., et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8 (2002) 68-74
69. Edery P., Lyonnet S., Mulligan L.M., et al. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 367 (1994) 378-380
70. Hofstra R.M., Landsvater R.M., Ceccherini I., et al. Mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367 (1994) 375-376
71. Asai N., Iwashita T., Matsuyama M., and Takahashi M. Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15 (1995) 1613-1619
72. Santoro M., Carlomagno F., Romano A., et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267 (1995) 381-383
73. Ludwing L., Kessler H., Wagner M., et al. Nuclear factor-κB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res 61 (2001) 4526-4535
74. Ivan M., and Kaelin W.G. The von Hippel-Lindau tumor suppressor protein. Curr Opin Gen Dev 11 (2001) 27-34
75. Qi H., and Ohh M. The von Hippel-Lindau tumor suppressor protein synthesizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by supressing the nuclear factor-κB-dependent antiapoptotic pathway. Cancer Res 63 (2003) 7076-7080
76. Lind M.H., Rozell B., Wallin R.P.A., et al. Tumor necrosis factor receptor 1-mediated signaling is required for skin cancer development induced by NF-κB inhibition. Proc Natl Acad Sci USA 101 (2004) 4972-4977
77. Wang C.Y., Mayo M.W., and Baldwin A.S.J. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science 274 (1996) 784-787
78. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., and Verma I.M. Suppression of TNF-induced apoptosis by NF-κB. Science 274 (1996) 787-789
79. Monks N.R., Biswas D.K., and Pardee A.B. Blocking anti-apoptosis as a strategy for cancer chemotherapy. NF-κB as a target. J Cell Biochem 92 (2004) 646-650
80. Frelin C., Imbert V., Griessinger E., et al. Targeting NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 105 (2005) 804-811
81. Huang P., Feng L., Oldham E.A., Deating M.J., and Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 407 (2000) 390-395
82. Karin M., Yamamoto Y., and Wang Q.M. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 3 (2004) 17-26
83. Orlowski R.Z., and Baldwin Jr. A.S. NF-κB as a therapeutic target in cancer. Trends Mol Med 8 (2002) 385-389
84. Yin M.-J., Yamamoto Y., and Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 396 (1998) 77-80
85. Wahl C., Liptay S., Adler G., and Schmid R.M. Sulfasalazine: a potent and specific inhibitor of NF-κB. J Clin Invest 101 (1997) 1163-1174
86. Auphan N., DiDonato J.A., Rosette C., Helmberg A., and Karin M. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270 (1995) 286-290
87. De Bosscher K., Berghe V., Vermeulen L., Plaisance S., Boone E., and Haegeman G. Glucocorticoids repress NF-κB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA 97 (2000) 3919-3924
88. Voorhees P.M., Dees E.C., O'Neil B., and Orlowski R.Z. The proteasome as a target for cancer therapy. Clin Cancer Res 9 (2003) 6316-6325
89. Aghajanian C., Soignet S., Dizon D., et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8 (2002) 2505-2511
90. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. New Engl J Med 348 (2003) 2609-2617
91. Egan L.J., Eckmann L., Greten F., et al. IκB-kinaseβ-dependent NF-κB activation provides radioprotection to the intestinal epithelium. Proc Natl Acad Sci USA 101 (2004) 2452-2457